ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND
0535.868.481 · rovalta.com · 26/09/2026
ANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBOANTIKANKERFONDS-FONDS ANTICANCER-ANTICANCER FUND is a Public utility foundation incorporated in 2013. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Meise. It employs on average 11,4 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0535.868.481
- Incorporation
- 21/06/2013
- Legal form
- Public utility foundation
- Registered office
- Brusselsesteenweg 11
1860 Meise · FlandreSee on map - Latest accounts
- 31/12/2025
- Average workforce
- 11,4 ETP
Joint committees (2)
- 200
- 337
Financials
Source · NBB, 10 filingsTrend over 9 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 2 M € | +28.4% | 1,6 M € | -4.6% | 1,6 M € | +16381% | 9,9 k € | -99.0% | 952,9 k € |
| EBITDA | 596,3 k € | +161% | 228,2 k € | -50.1% | 457,7 k € | +148% | -956,3 k € | -4160% | 23,6 k € |
| Operating result | 548,8 k € | +218% | 172,5 k € | -58.5% | 415,5 k € | +142% | -989,6 k € | -21411% | -4,6 k € |
| Net result | 584,4 k € | +150% | 233,6 k € | -47.3% | 443,4 k € | +144% | -998,9 k € | -16545% | -6 k € |
| Balance sheet | |||||||||
| Equity | 5,3 M € | +17.1% | 4,5 M € | +5.4% | 4,3 M € | +11.5% | 3,9 M € | -20.5% | 4,9 M € |
| Total assets | 6 M € | +23.8% | 4,8 M € | +5.4% | 4,6 M € | +11.7% | 4,1 M € | -18.7% | 5,1 M € |
| Cash | 2,7 M € | +83.6% | 1,5 M € | -16.4% | 1,8 M € | -51.7% | 3,7 M € | -15.5% | 4,3 M € |
| Debts | 481,8 k € | +77.6% | 271,3 k € | +6.9% | 253,8 k € | +5.9% | 239,6 k € | +29.3% | 185,3 k € |
| Other | |||||||||
| Workforce | 11,4 ETP | +11.8% | 10,2 ETP | +5.2% | 9,7 ETP | +11.5% | 8,7 ETP | +1.2% | 8,6 ETP |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20256 active · 4 ended
Active mandates
Ended mandates
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 17/06/2026 | 10/06/2025 | 09/07/2024 | 10/07/2023 | 15/06/2022 | 28/07/2021 |
| General meeting | 17/06/2026 | 04/06/2025 | 18/06/2024 | 28/06/2023 | 08/06/2022 | 10/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 10 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 17/06/2026 | 17/06/2026 | Dutch | |
| Abridged model | 31/12/2024 | 04/06/2025 | 10/06/2025 | Dutch | |
| Abridged model | 31/12/2023 | 18/06/2024 | 09/07/2024 | Dutch | |
| Abridged model | 31/12/2022 | 28/06/2023 | 10/07/2023 | Dutch | |
| Abridged model | 31/12/2021 | 08/06/2022 | 15/06/2022 | Dutch | |
| Abridged model | 31/12/2020 | 10/06/2021 | 28/07/2021 | Dutch | |
| Abridged model | 31/12/2019 | 05/06/2020 | 08/06/2020 | Dutch | |
| Abridged model | 31/12/2018 | 01/06/2019 | 06/06/2019 | Dutch | |
| Abridged model | 31/12/2017 | 01/06/2018 | 04/06/2018 | Dutch | |
| Abridged model | 31/12/2016 | 05/06/2017 | 28/07/2017 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 5 M€ and 10 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20256 active · 4 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Mandates26/02/2026ONTSLAGEN - BENOEMINGEN
- Mandates13/09/2022ONTSLAGEN - BENOEMINGEN
- Mandates05/04/2022BENAMING - MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
- Mandates29/10/2018BENAMING - ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM
- Mandates09/11/2015ONTSLAGEN - BENOEMINGEN
- Other02/07/2013RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025584,4 k €↑
- 2024Annual accounts 2024233,6 k €↓
- 2023Annual accounts 2023443,4 k €↑
- 2022Annual accounts 2022-998,9 k €↓
- 2021Annual accounts 2021-6 k €↓
- 2021Name changeANTIKANKERFONDS - FONDS ANTICANCER - ANTICANCER FUND
- 2019Annual accounts 20191,1 M €↑
- 2018Annual accounts 2018332,6 k €↑
- 2017Annual accounts 2017-419,7 k €↓
- 2016Annual accounts 20161,2 M €
- 2016Name changeHET ANTI-KANKERFONDS - LE FONDS ANTI-CANCER
- 21/06/2013IncorporationPublic utility foundation